Zoetis Inc. $ZTS Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 239,911 shares of the company’s stock after selling 28,481 shares during the period. PNC Financial Services Group Inc.’s holdings in Zoetis were worth $35,104,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ZTS. North Star Asset Management Inc. increased its holdings in shares of Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after buying an additional 67 shares during the last quarter. Moment Partners LLC grew its position in Zoetis by 3.2% during the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after acquiring an additional 72 shares during the period. CVA Family Office LLC grew its position in Zoetis by 6.7% during the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after acquiring an additional 74 shares during the period. Bank of Nova Scotia Trust Co. increased its stake in Zoetis by 4.6% during the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after acquiring an additional 74 shares during the last quarter. Finally, RWA Wealth Partners LLC raised its holdings in shares of Zoetis by 2.7% in the 2nd quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock worth $445,000 after purchasing an additional 76 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.8%

ZTS opened at $126.64 on Tuesday. The firm’s 50 day moving average is $124.59 and its 200-day moving average is $135.21. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $53.46 billion, a P/E ratio of 21.04, a P/E/G ratio of 2.12 and a beta of 0.96.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZTS. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Piper Sandler reiterated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.